Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

  • Exchange: Frankfurt
  • Sector: Health Care
  • Industry: Biotech & Pharma
  • Sub-Industry: Specialty Pharma

Progenics Pharmaceuticals Inc

+ Add to Watchlist


4.937 EUR 0.163 3.20%

As of 08:28:09 ET on 05/29/2015.

Snapshot for Progenics Pharmaceuticals Inc (PGP)

Open: 4.952 Day's Range: 4.929 - 5.025 Volume: 0
Previous Close: 5.100 52wk Range: 2.435 - 6.792 1-Yr Rtn: +62.83%

Stock Chart for PGP

No chart data available.
  • PGP:GR 5.025
  • 1D
  • 1M
  • 1Y
Interactive PGP Chart

Previous Close

No chart data available.
Interactive Chart
  • 1D
  • 1W
  • 1M
  • YTD
  • 1Y
  • 3Y
  • 5Y
Recently Viewed Symbols
Save as Watchlist
Saving as watchlist...

Key Statistics for PGP

Current P/E Ratio (ttm) -
Estimated P/E(12/2015) -
Relative P/E vs. DAX -
Earnings Per Share (USD) (ttm) -
Est. EPS (USD) (12/2015) -0.5280
Est. PEG Ratio -
Market Cap (M EUR) 343.84
Shares Outstanding (M) 69.64
30 Day Average Volume 224
Price/Book (mrq) -
Price/Sale (ttm) -
Dividend Indicated Gross Yield -%
Cash Dividend -
Dividend Ex-Date
5 Year Dividend Growth -
Next Earnings Announcement 08/07/2015
mrq = Most Recent Quarter; ttm = Trailing Twelve Months

Income Statement for PGP

  • Revenue
  • Net Income (M/USD)
  • Profit Margin (%)

Company Profile & Key Executives for PGP

Progenics Pharmaceuticals, Inc. is a biopharmaceutical company. The Company develops and distributes therapeutic products to treat the unmet medical needs of patients with debilitating conditions and life-threatening diseases. Progenics' principal programs are directed toward supportive care, virology (human immunodeficiency virus and hepatitis C virus infections), and oncology.

Mark Robert BakerChief Executive OfficerVivien WongExec VP:Development
Robert J IsraelExec VP:InnovationNitya G RaySenior VP:Manufacturing
More Company Profile & Key Executives for PGP

Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.

Sponsored Link
Sponsored Links
sec ||= nil